Is Gilead Sciences (GILD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 14.0% / 30% | 5.4% / 30% | 2.7% / 30% | 1.19% / 5% | ✓ HALAL |
| DJIM | 14.0% / 33% | 5.4% / 33% | 2.7% / 33% | 1.19% / 5% | ✓ HALAL |
| MSCI | 42.2% / 33% | 16.3% / 33% | 8.3% / 33% | 1.19% / 5% | ✗ NOT HALAL |
| S&P | 14.0% / 33% | 5.4% / 33% | 2.7% / 33% | 1.19% / 5% | ✓ HALAL |
| FTSE | 42.2% / 33% | 16.3% / 33% | 8.3% / 50% | 1.19% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 78.8% | |
| Operating Margin | 37.4% | |
| Net Margin | 28.9% | |
| Return on Equity (ROE) | 40.7% | |
| Return on Assets (ROA) | 12.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $10.0B |
| Free Cash Flow | $9.5B |
| Total Debt | $24.9B |
| Debt-to-Equity | 112.9 |
| Current Ratio | 1.6 |
| Total Assets | $59.0B |
Price & Trading
| Last Close | $136.88 |
| 50-Day MA | $143.41 |
| 200-Day MA | $123.67 |
| Avg Volume | 7.1M |
| Beta | 0.4 |
|
52-Week Range
$93.37
| |
About Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Purification Calculator
As a halal stock with 1.19% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Gilead Sciences (GILD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Gilead Sciences is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Gilead Sciences's debt ratio?
Gilead Sciences's debt ratio is 14.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 42.2%.
Does Gilead Sciences require dividend purification?
Yes, Gilead Sciences has an impermissible income ratio of 1.19%, which means 1.19% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Gilead Sciences's key financial metrics?
Gilead Sciences has a market capitalization of $166.6B, trailing P/E ratio of 19.8, and revenue of $29.4B. The company maintains a gross margin of 78.8% and a net margin of 28.9%. Return on equity stands at 40.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.